- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02693613
Pharmacokinetic Study of ASP1517 With Kremezin®
June 17, 2016 updated by: Astellas Pharma Inc
Pharmacokinetic Study of ASP1517 - Evaluation of the Effect of Kremezin® on the Pharmacokinetics of ASP1517 in Non-elderly Healthy Adult Male Subjects, When Administered Concomitantly or in a Time Separated Manner.
The objective of this study is to evaluate the effect of Kremezin® on the pharmacokinetics of single dose of ASP1517 in healthy non-elderly adult male subjects when administered concomitantly or in a time separated manner.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
34
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Tokyo, Japan
- Site JP00001
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 44 years (ADULT)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Body weight (at screening): ≥50.0 kg and <80.0 kg
- Body-mass index (BMI) (at screening): ≥17.6 and <26.4 kg/m2
- Subject must agree to use contraception consisting of two established forms (1 of which must be a barrier method) starting at the time of informed consent and continuing throughout the treatment period and for 84days after ASP1517 administration in the last period:
- Subject must agree not to donate sperm starting at the time of informed consent and continuing throughout 84 days after the last administration of ASP1517 in the last period.
Exclusion Criteria:
- Received or is scheduled to receive any investigational drugs in other clinical trials or post-marketing studies within 120 days before screening or during the period from screening to the hospital admission day of the Period 1 (Day -1).
- Received or is scheduled to receive medications (including over-the-counter [OTC] drugs) within 7 days before the hospital admission day of the Period 1 (Day -1).
- Received or is scheduled to receive supplements within 7 days before the hospital admission day of the Period 1 (Day -1).
- Deviates from any of the normal range of blood pressure, pulse rate, body temperature and standard 12-lead electrocardiogram (ECG) specified at screening or the hospital admission day of the Period 1 (Day -1).
- Meets any of the following criteria for laboratory tests at screening or the hospital admission day of the Period 1 (Day -1). Normal ranges of each test specified at the study site or the test/assay organization will be used as the normal ranges in this study.
- Concurrent or previous drug allergies.
- Development of (an) upper gastrointestinal symptoms within seven days before the hospital admission day of the Period 1 (Day -1).
- Concurrent or previous hepatic disease, heart disease, respiratory disease, gastrointestinal disease, gastrointestinal obstruction,oesophageal varices, renal disease, endocrine disease, cerebrovascular disorder, malignant tumor, retinal neovascular lesions and macular edema.
- Concurrent chronic constipation or diarrhoea.
- A history of digestive tract excision.
- Previous use of hypoxia inducible factor-prolyl hydroxylase inhibitors (HIF-PHI) such as ASP1517 (FG-4592), YM311 (FG-2216) or erythropoietin products.
- Excessive alcohol or smoking habit.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Group 1
Treatment arm includes 4 periods, single dose of ASP1517 alone, single dose of ASP1517 + Kremezin® without a time lag, single dose of ASP1517 + Kremezin® with a time lag (1 h before ASP1517 administration) and single dose of ASP1517 + Kremezin® with a time lag (1 h after ASP1517 administration)
|
Oral
Oral
|
Experimental: Group 2
Treatment arm includes 3 periods, single dose of ASP1517 alone, single dose of ASP1517 + Kremezin® with a time lag (2 h before ASP1517 administration) and single dose of ASP1517 + Kremezin® with a time lag (2 h after ASP1517 administration)
|
Oral
Oral
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pharmacokinetics (PK) parameter of ASP1517: AUCinf
Time Frame: Pre-dose, 0.5, 1, 2, 3, 5, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hr after dosing
|
AUCinf: Area under the concentration-time curve from the time of dosing extrapolated to time infinity
|
Pre-dose, 0.5, 1, 2, 3, 5, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hr after dosing
|
PK parameter of ASP1517: Cmax
Time Frame: Pre-dose, 0.5, 1, 2, 3, 5, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hr after dosing
|
Cmax: Maximum concentration
|
Pre-dose, 0.5, 1, 2, 3, 5, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hr after dosing
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PK parameters of ASP1517: AUClast
Time Frame: Pre-dose, 0.5, 1, 2, 3, 5, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hr after dosing
|
AUClast: Area under the concentration-time curve from the time of dosing extrapolated to the last measurable concentration
|
Pre-dose, 0.5, 1, 2, 3, 5, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hr after dosing
|
PK parameters of ASP1517: CL/F
Time Frame: Pre-dose, 0.5, 1, 2, 3, 5, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hr after dosing
|
CL/F: Apparent total systemic clearance
|
Pre-dose, 0.5, 1, 2, 3, 5, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hr after dosing
|
PK parameters of ASP1517: t1/2
Time Frame: Pre-dose, 0.5, 1, 2, 3, 5, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hr after dosing
|
t1/2: Terminal elimination half-life
|
Pre-dose, 0.5, 1, 2, 3, 5, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hr after dosing
|
PK parameters of ASP1517: tmax
Time Frame: Pre-dose, 0.5, 1, 2, 3, 5, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hr after dosing
|
tmax: Time of Cmax
|
Pre-dose, 0.5, 1, 2, 3, 5, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hr after dosing
|
PK parameters of ASP1517: tlag
Time Frame: Pre-dose, 0.5, 1, 2, 3, 5, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hr after dosing
|
tlag: Time point prior to the time point corresponding to the first measurable (non-zero) concentration
|
Pre-dose, 0.5, 1, 2, 3, 5, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hr after dosing
|
PK parameters of ASP1517: Vz/F
Time Frame: Pre-dose, 0.5, 1, 2, 3, 5, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hr after dosing
|
Vz/F: Apparent volume of distribution during the terminal elimination phase
|
Pre-dose, 0.5, 1, 2, 3, 5, 6, 8, 12, 16, 24, 36, 48, 60 and 72 hr after dosing
|
Safety assessed by Adverse events
Time Frame: Up to 72 hours after final study drug dosing
|
Up to 72 hours after final study drug dosing
|
|
Safety assessed by Vital signs
Time Frame: Up to 72 hours after each study drug dosing
|
Supine blood pressure, supine pulse rate and axillary body temperature
|
Up to 72 hours after each study drug dosing
|
Safety assessed by Laboratory tests
Time Frame: Up to 72 hours after each study drug dosing
|
Hematology, blood biochemistry and urinalysis
|
Up to 72 hours after each study drug dosing
|
Safety assessed by Standard 12-lead ECG
Time Frame: Up to 72 hours after each study drug dosing
|
ECG: Electrocardiogram
|
Up to 72 hours after each study drug dosing
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2016
Primary Completion (Actual)
April 1, 2016
Study Completion (Actual)
April 1, 2016
Study Registration Dates
First Submitted
February 3, 2016
First Submitted That Met QC Criteria
February 23, 2016
First Posted (Estimate)
February 29, 2016
Study Record Updates
Last Update Posted (Estimate)
June 21, 2016
Last Update Submitted That Met QC Criteria
June 17, 2016
Last Verified
May 1, 2016
More Information
Terms related to this study
Other Study ID Numbers
- 1517-CL-0204
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Volunteers
-
AstraZenecaCompletedHealthy Elderly Volunteers | Healthy Young VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
Syndax PharmaceuticalsCompletedHealthy Volunteers | Volunteers | Normal Volunteers | Human VolunteersUnited States
-
University Hospital, Clermont-FerrandUnite de Nutrition Humaine UMR 1019- INRAE; Unite MetaGenoPolis INRAE; France...CompletedHealthy Volunteers | Frail VolunteersFrance
-
Galera Therapeutics, Inc.CelerionCompletedHealthy | Healthy VolunteersUnited States
-
Newcastle UniversityCompletedGI Glycaemic Index Healthy Volunteers | GL Glycaemic Load Healthy VolunteersUnited Kingdom
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
PMV Pharmaceuticals, IncRecruitingHealthy VolunteersUnited States
Clinical Trials on ASP1517
-
Astellas Pharma IncFibroGenCompletedChronic Kidney DiseaseJapan
-
Astellas Pharma IncFibroGenCompletedESA-naive Hemodialysis Chronic Kidney Disease Patients With AnemiaJapan
-
Astellas Pharma IncFibroGenCompletedPeritoneal Dialysis Chronic Kidney Disease Patients With AnemiaJapan
-
Astellas Pharma IncFibroGenCompleted
-
Astellas Pharma IncCompletedAnemia in Chronic Kidney Disease Patients Not on DialysisJapan
-
Astellas Pharma Global Development, Inc.FibroGenCompletedHealthy Adult SubjectsGermany
-
Astellas Pharma IncCompletedAnemia | Hemodialysis | Renal ImpairmentJapan
-
Astellas Pharma Europe B.V.FibroGenCompletedImpaired Renal Function | Normal Renal FunctionGermany, United Kingdom
-
Astellas Pharma IncFibroGenCompletedHemodialysis Patients With Renal AnemiaJapan
-
Astellas Pharma IncActive, not recruiting